Sixfold Bioscience Inc, the RNA Architects, today announced that the Company will participate in the 3rd RNAi-Based Therapeutics Summit in Boston, USA.
Sixfold will join the panel discussion on 'Delivery Carriers for Efficient siRNA Therapies', represented by Dr. Ioanna Mylonaki, Head of Preclinical R&D at Sixfold, on Wednesday, 20th of April, at 9:45 a.m. EDT.
Dr. Mylonaki will further coordinate the round table discussion on 'Effective Cell & Tissue Specificity for siRNA Therapeutics'.
Details on the program and participants of the 3rd RNAi-Based Therapeutics Summit can be found here.
Sixfold Bioscience is a venture-backed preclinical-stage biotechnology company, founded in 2017, based at the Translation & Innovation Hub in White City, London. Sixfold develops programmable drug delivery systems, with a current focus on short interfering RNA for gene silencing and messenger RNA for gene expression.
Sixfold’s RNA delivery platform, Mergo®, was conceived by co-founders Dr Perdrix Rosell and Dr George Foot, who were left frustrated by current delivery systems that were either too toxic or faced complex engineering challenges. The Company’s differentiated approach is based on engineering biocompatible nano-architectures with precise chemical profiles that guide the RNA to selected organs.
UK pumps £13M into wide-ranging group of manufacturing projects
August 22, 2023Read more
Sixfold Bioscience Announces Formation of Scientific Advisory Board
August 9, 2023Read more
Sixfold Bioscience joins UK biotech leaders in Parliament
July 5, 2023Read more
A revolution in targeted RNA delivery [Nature Biopharma]
June 1, 2023Read more